WASHINGTON — The Biden administration will fine drugmakers who hiked prices faster than the rate of inflation on 27 medications administered in physicians’ offices, the agency said Wednesday.
Pfizer had the most drugs on the list of any manufacturer, with five. Seagen’s bladder cancer drug Padcev, which also garnered penalties, will likely soon be in Pfizer’s portfolio, too, after the pharma giant completes its $43 billion acquisition of the Washington state company.
Create a display name to comment
This name will appear with your comment